Table 2.
Estimates of the SMD as summary measure for the difference in [18F]FDG (SUVmax) uptake between St. Gallen surrogate intrisic subtypes
| Comparisons | Studies | Patients | Meta-analysis | Subgroup | Egger | ||||
|---|---|---|---|---|---|---|---|---|---|
| No | I2 (%) | SMD | 95% CI | P | P | P | |||
| Primary analyses | |||||||||
| LB versus | |||||||||
| LB | 11 | 1022 | 487 | 29.8 | − 0.49 | − 0.68, − 0.31 | 0.0001 | – | 0.8191 |
| LBHER2− | 6 | 234 | 373 | 32.5 | − 0.68 | − 0.97, − 0.38 | 0.0021 | – | 0.4378 |
| LBHER2+ | 6 | 234 | 142 | 54.2 | − 0.72 | − 1.17, − 0.28 | 0.0089 | – | 0.2371 |
| HER2+ | 15 | 1024 | 290 | 56.4 | − 0.91 | − 1.21, − 0.61 | < 0.0001 | – | 0.6148 |
| TNBC | 17 | 1054 | 440 | 63.8 | − 1.21 | − 1.57, − 0.85 | < 0.0001 | – | 0.7310 |
| LB versus | |||||||||
| HER2+ | 9 | 369 | 185 | 61.2 | − 0.32 | − 0.88, 0.24 | 0.2244 | – | 0.8729 |
| TNBC | 10 | 405 | 279 | 36.0 | − 0.77 | − 1.05, − 0.49 | 0.0002 | – | 0.5091 |
| LBHER2− versus | |||||||||
| LBHER2+ | 6 | 373 | 142 | 66.0 | − 0.02 | − 0.52, 0.48 | 0.9316 | – | 0.1000 |
| HER2+ | 6 | 373 | 105 | 51.7 | − 0.33 | − 0.81, 0.14 | 0.1305 | – | 0.4260 |
| TNBC | 6 | 373 | 157 | 49.5 | − 0.58 | − 1.02, − 0.15 | 0.0177 | – | 0.7121 |
| LBHER2+ versus | |||||||||
| HER2+ | 7 | 189 | 129 | 0.0 | − 0.22 | − 0.43, − 0.01 | 0.0457 | – | 0.3950 |
| TNBC | 8 | 220 | 198 | 60.7 | − 0.45 | − 0.98, 0.08 | 0.0864 | – | 0.2661 |
| HER2+ versus | |||||||||
| TNBC | 17 | 326 | 492 | 58.1 | − 0.29 | − 0.61, 0.02 | 0.0667 | – | 0.6702 |
| TNBC versus | |||||||||
| Non-TNBC | 13 | 283 | 1157 | 0.0 | 0.56 | 0.41, 0.70 | < 0.0001 | – | 0.1236 |
| Sensitivity analyses | |||||||||
| LA versus | |||||||||
| LB | 16 | 1361 | 1103 | 58.1 | − 0.46 | − 0.64, − 0.28 | < 0.0001 | 0.6555 | 0.4305 |
| LBHER2− | 7 | 309 | 522 | 54.9 | − 0.60 | − 0.90, − 0.31 | 0.0025 | 0.0213 | 0.1428 |
| LBHER2+ | 7 | 309 | 176 | 46.4 | − 0.71 | − 1.07, − 0.36 | 0.0026 | 0.7466 | 0.3720 |
| HER2+ | 21 | 1438 | 706 | 59.0 | − 0.85 | − 1.08, − 0.62 | < 00,001 | 0.4906 | 0.6625 |
| TNBC | 24 | 1499 | 865 | 76.5 | − 1.18 | − 1.48, − 0.88 | < 0.0001 | 0.7134 | 0.6259 |
| LB versus | |||||||||
| HER2-pure | 14 | 985 | 579 | 58.1 | − 0.37 | − 0.67, − 0.08 | 0.0170 | 0.5380 | 0.3568 |
| TNBC | 15 | 1021 | 614 | 49.4 | − 0.75 | − 0.95, − 0.55 | < 0.0001 | 0.7621 | 0.2725 |
| LBHER2− versus | |||||||||
| LBHER2+ | 7 | 522 | 176 | 65.3 | − 0.09 | − 0.52, 0.33 | 0.6078 | 0.1151 | 0.0428 |
| HER2+ | 7 | 522 | 139 | 42.4 | − 0.37 | − 0.73, − 0.01 | 0.0454 | 0.6619 | 0.3687 |
| TNBC | 7 | 522 | 233 | 45.1 | − 0.53 | − 0.86, − 0.21 | 0.0073 | 0.3633 | 0.4680 |
| LBHER2+ versus | |||||||||
| HER2+ | 8 | 223 | 151 | 0.0 | − 0.17 | − 0.37, 0.02 | 0.0745 | 0.3306 | 0.3426 |
| TNBC | 9 | 254 | 274 | 62.3 | − 0.37 | − 0.84, 0.10 | 0.1103 | 0.0792 | 0.1436 |
| HER2+ versus | |||||||||
| TNBC | 24 | 754 | 916 | 45.2 | − 0.25 | − 0.45, − 0.06 | 0.0130 | 0.9067 | 0.3980 |
| TNBC versus | |||||||||
| Non-TNBC | 19 | 379 | 1516 | 40.6 | 0.73 | 0.54, 0.90 | < 0.0001 | 0.0015 | 0.0526 |
Data derived from the primary and sensitivity analyses are presented
CI, confidence interval; HER2, human epidermal growth factor 2 receptor; LA, luminal A; LB, luminal B; SMD, standardized mean difference; TNBC, triple negative breast cancer